clinical trial · NCT07614191
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases
Vivacta Biotechnology (Shanghai) Co., Ltd.·early phase1·not yet recruiting·n = 22
Moderate to Severe Refractory Autoimmune DiseasesGT801 Injection
brief summary
This study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the safety, efficacy and cellular pharmacokinetics of GT801 injection in patients with moderate to severe refractory autoimmune diseases.
started
May 1, 2026
primary completion
Dec 30, 2031
completion
Dec 30, 2031
last updated
May 29, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol